Realm Reaches End of The Road And Seeks Buyer

The US company listed in the UK has been devastated by the failure of its investigational eczema drug in Phase II trials in August and has hired an advisor to look for strategic alternatives, including a sale.

Dead end
Failures in the clinic spell the end for Realm Therapeutics • Source: Shutterstock

The writing is on the wall for Realm Therapeutics which has decided to discontinue all of its drug development programs and put up the 'for sale' sign following the high-profile failure this summer of its mid-stage atopic dermatitis candidate.

Realm, which is listed on London's AIM exchange but is based in Malvern, PA, has been struggling since August when...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category